Elderly patients with metastatic castrate-resistant prostate cancer (mCRPC): Safety and efficacy of docetaxel retreatment. Background: Medical castration using gonadotropin-releasing hormone (GnRH) ...

Triptorelin market value is predicted to reach USD 1.49 billion by 2032, according to a new research report by Global Market Insights Inc. Rising awareness about precocious puberty is a key driver ...

Review the side-effects of Triptorelin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The global triptorelin market is set for substantial growth, according to the latest market analysis report. Forecasts indicate that the market, valued at approximately USD 955.50 million in 2023, is ...

Please provide your email address to receive an email when new articles are posted on . Women with polycystic ovary syndrome have less increase in follicle-stimulating hormone after triptorelin ...

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...

Details concerning the Triptorelin Pamoate for Injectable Suspension medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ...

Chemotherapy for breast cancer in premenopausal women causes menopause (premature ovarian failure) in a variable proportion of patients, ranging from 0% to 90% depending on the treatment received and ...

Gonadotropin-releasing hormone (GnRH) agonists are more effective and safe compared to estrogens and anti-androgens used to attain medical castration. GnRH agonists offer slow-release formulations ...

Prostate cancer depends on testosterone to grow. Testosterone is a type of sex hormone that your body naturally produces. Triptorelin blocks messages from the brain that normally tell the body to make ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality ...